MedPath

Evaluating Telementoring for CHW-centered Diabetes Initiatives

Not Applicable
Active, not recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
Other: Intervention
Registration Number
NCT04835493
Lead Sponsor
The University of Texas Medical Branch, Galveston
Brief Summary

Diabetes care is complex and requires a multidimensional approach, but interventional programs are difficult to initiate in low-income and minority populations. In the proposed study, investigators will mentor local clinics via telehealth to initiate our diabetes program involving telehealth-support, integrated CHWs, medication-access, and diabetes Education into their clinics. Mentoring local clinics to initiate this intervention is a promising strategy to enhance sustainable diabetes care and reduce disparities in vulnerable minority populations.

Detailed Description

Diabetes is a major public health problem in Latino(a)s. There are escalating numbers of Latino(a)s diagnosed with diabetes and at disproportionate rates compared to other ethnicities. Numerous interventions have been initiated to improve minority healthcare including diabetes group visits, which have been valuable in improving education and glycemic control. In our group visit investigations, investigators initiated Community Health Workers (CHWs)-local community members who serve as culturally-sensitive patient liaisons to the healthcare system-as part of the multidisciplinary team. Investigators demonstrated that CHWs are vital team members and particularly helpful in identifying medication-access barriers. However, CHWs are frontline workers and often left unsupported and poorly supervised. Investigators used these data to pioneer the combination of four diabetes interventions. This trial showed that individuals randomized to the intervention significantly improved glycemic control, blood pressure and adherence to American Diabetes Association standards compared to usual care. The study also showed that telehealth (mobile health (mHealth) and ZOOM video conferencing) was instrumental in supporting CHWs in their work and enhancing their communication with patients.

The COVID-19 pandemic has highlighted the expansive use of telehealth and its ability to improve healthcare. It has also underscored the pressing need to improve care for low-income minorities. Though diabetes programs are valuable in improving education and clinical outcomes, they are often difficult to initiate in low-income settings. Pragmatic implementation using telehealth to mentor local clinic teams of providers and CHWs is promising to address these barriers. Investigators have pilot data showing the feasibility of telementoring a local clinic to initiate our program that has resulted in improved HbA1c levels but it needs to be tested within a larger sample. In the proposed study investigators will evaluate this approach in a randomized clinical trial (N=320; intervention=160) of low-income, adult Latino(a)s with type 2 diabetes randomized to the diabetes program intervention versus usual care (UC). Our research group will provide telementoring to local clinic teams to initiate our program into their clinics. To evaluate efficacy, investigators will compare the intervention versus UC clinical changes including HbA1c (primary outcome), blood pressure, cholesterol, and body mass index from baseline to 12-months (AIM 1). To compare longitudinal data of study arms, investigators will follow these clinical measures until 36 months (AIM 2). Investigators will also provide program acceptability and evaluation data for participants and clinic teams from baseline to 12-months (AIM 3). Investigators hypothesize that intervention participants will have superior and more sustainable clinical outcomes compared to UC individuals and that the intervention will have high levels of acceptability and evaluation data. Investigators anticipate that the proposed study will provide justification of telementoring to initiate the intervention and strong evidence to improve the longitudinal care of low-income Latino(a)s with diabetes.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
320
Inclusion Criteria
  • self-identified Latino(a)
  • Spanish-speaking
  • >/=18 years
  • type 2 diabetes (T2D), e.g., HbA1c >/=6.5%, provider documented T2D, on oral anti-hyperglycemic
  • uninsured, <150% federal poverty level
Exclusion Criteria
  • no show to all group visits
  • condition that may alter HbA1c levels, e.g., recent blood transfusion
  • patients at high-risk or not appropriate for care in a group setting e.g., pregnancy, severe cognitive impairment, frequent clinic appointments for labile glucose/medication titration e.g., insulin.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionInterventionIntervention individuals will receive the 12-month diabetes program
Usual Care (UC)InterventionWe will define UC as usual clinical care, which consists of diabetes management provider encounters (mean quarterly) plus monthly individual appointments with a pharm-Ds or nutritionists as clinically indicated. In addition, clinics offer multiple other individual and group opportunities.
Primary Outcome Measures
NameTimeMethod
HbA1cBaseline to 12-months

Compare intervention versus control HbA1c levels

Secondary Outcome Measures
NameTimeMethod
Sustainable clinical outcomes: HbA1cbaseline to 36-months

Compared to control, the intervention will have more sustainable HbA1c levels

ADA adherence measures: B12 screeningBaseline to 12-months

Compare intervention versus control adherence to B12 screening

ADA adherence measures: flu vaccinationBaseline to 12-months

Compare intervention versus control adherence to flu vaccination

Sustainable clinical outcomes: BMIbaseline to 36-months

Compared to control, the intervention will have more sustainable BMI levels

Community Health Worker (CHW) knowledge12-months

At 12-months; Knowledge as measured the CHW posttest, which includes 24-questions from the Star Education Study diabetes knowledge test, which has shown validity and reliability in English and Spanish and our TIME 25-question diabetes medication test that has been previously published. Tests are multiple choice with 4 possible answers.

Program satisfaction12-months

Anticipate \>/=80% patient satisfaction as demonstrated by our 12-question satisfaction survey questions (on Likert scales of 1 to 10 (n=5 questions) where 10 is very satisfied and 1 is not at all satisfied and from 1-4 (n=3 questions) where 4 is very satisfied and 1 is not satisfied). There are three open-ended questions.

Body Mass Index (BMI)Baseline to 12-months

Compare intervention versus control BMI levels

ADA adherence measures: urine microalbumin screeningBaseline to 12-months

Compare intervention versus control adherence to urine microalbumin screening

ADA adherence measures: statin therapyBaseline to 12-months

Compare intervention versus control adherence to statin therapy

Blood pressureBaseline to 12-months

Compare intervention versus control blood pressure levels (systolic and diastolic)

CholesterolBaseline to 12-months

Compare intervention versus control cholesterol levels

ADA adherence measures: Diabetes eye examBaseline to 12-months

Compare intervention versus control adherence to diabetes eye exams

American Diabetes Association (ADA) adherence measures: Diabetes foot examBaseline to 12-months

Compare intervention versus control adherence to diabetes foot exams

Sustainable clinical outcomes: Blood pressurebaseline to 36-months

Compared to control, the intervention will have more sustainable blood pressure levels (systolic and diastolic)

Attritionbaseline to 12-months

Rate of attrition for intervention participants

Telehealth Acceptability12-months

Acceptability as measured by the Telehealth Usability Questionnaire, a 21-question survey of telehealth acceptability. Items are ranked on a 5-item scale (1 not acceptable, 5 very acceptable) and divided into six subsections that have shown good to excellent internal consistency.

Trial Locations

Locations (1)

University of Texas Medical Branch

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath